OMass Therapeutics raises $310M in one of Europe’s largest biotech rounds

OMass Therapeutics, a U.K.-based biotech startup, has closed a $310 million funding round led by Novo Holdings, Bain Capital, and Forbion, MarketWatch reported. The deal ranks among the largest European biotech financings this year.

The capital will fund progression of OMass’s lead programs into late-stage clinical trials, according to company statements cited by the outlet. No specific drug targets or therapeutic areas were disclosed in the announcement.

Investor participation reflects sustained confidence in European biotech after a period of relative drought for large rounds. Novo Holdings and Forbion have both backed earlier OMass financings, while Bain Capital’s involvement follows its rapid follow-on investment in healthcare automation startup Forus just weeks ago, as StartupReader covered on 8 September.

The size of the round also contrasts with recent seed and early-stage activity across Europe, including Zero’s $10.3 million seed reported on 17 September. With no prior StartupReader directory listing for OMass, the deal offers little visibility into the company’s pipeline beyond its stated focus on novel drug discovery platforms. Observers will watch whether the funding heralds a broader rebound in late-stage biotech investment or remains an outlier.

Sources: marketwatch.com